EUCTR2012-000057-31-BE进行中（未招募）1 期
Multicentre, randomised, double-blind, parallel, placebo-controlled study evaluating the efficacy and safety of Early Self-Treatment of viral Upper respiratory tract infections with homeopathic oral Antibodies to the TLR3 FYW peptide (TAO1) - ESTUAR Study
THERANOR sprl0 个研究点开始时间: 2012年1月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Outpatients aged > or = 18 years
- •b) Ability and willingness to adhere to the study protocol
- •c) Signed informed consent
- •d) Self-reported recently emerged symptoms of common cold: answer Yes to the question Do you believe that you are coming down with a cold?
- •e) At least one of the following 4 common cold symptoms: sneezing, runny nose, nasal obstruction and/or sore throat, with no limitations of symptom severity.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •a) Specific chronic diseases (autoimmune disease, chronic
- •bronchitis, human immunodeficiency virus (HIV) infection, lupus, rheumatoid arthritis)
- •b) Malignancy for which the patient has undergone resection, radiation or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
- •c) Cancer therapy
- •d) Immunosuppressant therapies
- •e) Use of systemic corticosteroids
- •f) A history of asthma or allergic rhinitis and corresponding symptoms (itchy eyes, sneezing, wheezing)
- •g) Any of the common cold symptoms persisting since more than 36 hours
- •h) Use of other homeopathic drugs designed to treat URTIs
- •i) Use of antibiotics, anti-histaminergic drugs or decongestants
- •j) Participation in another clinical trial within one month prior to treatment start
- •k) Previous participation (receipt of randomised treatment) in this study
研究者
相似试验
已完成
不适用
Multicentre, randomised, double-blind, parallel-group, placebo-controlled clinical trial, comparing nateglinide versus placebo to assess the efficacy and tolerability of nateglinide in patients with type two diabetes mellitusType two diabetes mellitus with more than five years of evolutionNutritional, Metabolic, EndocrineDiabetesISRCTN04296019ovartis Pharma (Novartis Farmacéutica SA) (Spain)102
进行中（未招募）
1 期
Pharmacogenomics of antiVEGF in patients with Age-Associated Macular Degeneration.age-related macular degenerationEUCTR2019-003204-12-ESConsorcio PSMAR630
进行中（未招募）
1 期
Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinenceEUCTR2004-001116-31-ESaboratorios Dr. Esteve S.A.690
进行中（未招募）
不适用
Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800 mg/d), placebo, and tolterodine 2 mg bid (4 mg/d) in the treatment of urge urinary incontinencerge Urinary IncontinenceEUCTR2004-001116-31-GBaboratorios Dr. Esteve S.A.690
进行中（未招募）
1 期
Vehicle controlled study to evaluate the efficacy and safety of Actikerall® solution in the field-directed treatment of actinic keratoses grade I to IIEUCTR2014-001171-31-GBAlmirall Hermal GmbH162